CORRECTION article

Front. Immunol., 17 April 2024

Sec. Cancer Immunity and Immunotherapy

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1403324

Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer

  • 1. Department of Laboratory Medicine, Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Center of Growth, Metabolism and Aging, State Key Laboratory of Biotherapy and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, Sichuan, China

  • 2. Department of Obstetrics and Gynecology, Chengdu Second People’s Hospital, Chengdu, Sichuan, China

  • 3. Department of Clinical Laboratory, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, China

In the published article, there was an error in Figure 1 as published. PCTF is a symporter that transport H+ ion together with the folate transporter, we made a mistake with the direction of one arrow, by making it like PCFT is portrayed as an antiporter. The corrected Figure 1 and its caption appear below.

Figure 1

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

ovarian cancer, folate receptor α, FOLR1, mirvetuximab soravtansine, MIRV, Elahere, antibody-drug conjugate, ADC

Citation

Mai J, Wu L, Yang L, Sun T, Liu X, Yin R, Jiang Y, Li J and Li Q (2024) Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer. Front. Immunol. 15:1403324. doi: 10.3389/fimmu.2024.1403324

Received

19 March 2024

Accepted

08 April 2024

Published

17 April 2024

Volume

15 - 2024

Edited and reviewed by

Nurit Hollander, Tel Aviv University, Israel

Updates

Copyright

*Correspondence: Yongmei Jiang, ; Jinke Li, ; Qintong Li,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics